We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Illumina Inc | NASDAQ:ILMN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.95 | 1.58% | 125.00 | 125.00 | 126.00 | 126.89 | 121.94 | 122.40 | 1,401,348 | 00:52:28 |
From May 2019 to May 2024
Gene-sequencing company Illumina Inc. cut its third-quarter revenue guidance and gave a dour view for the current quarter on a bigger-than-feared decline in sales of its high-volume sequencing instruments.
Shares, down 3.7% this year, fell 22% to $144 in recent after-hours trading.
The San Diego, Calif., company now expects revenue of roughly $607 million for the quarter ended in September, compared with its previous projection for revenue between $625 million and $630 million.
Illumina said it also expects fourth-quarter revenue will be flat to slightly higher than during the third quarter. Analysts polled by Thomson Reuters recently expected revenue of $684.6 million.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
October 10, 2016 18:25 ET (22:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Illumina Chart |
1 Month Illumina Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
